Common Oral Lesions: Part I. Superficial Mucosal Lesions
Am Fam Physician. 2007 Feb 15;75(4):501-506.
This is part I of a two-part article on oral lesions. Part II, “Masses and Neoplasia,” appears in this issue of AFP .
Patient information: See related handout on canker sores.
Common superficial oral lesions include candidiasis, recurrent herpes labialis, recurrent aphthous stomatitis, erythema migrans, hairy tongue, and lichen planus. Recognition and diagnosis require taking a thorough history and performing a complete oral examination. Knowledge of clinical characteristics such as size, location, surface morphology, color, pain, and duration is helpful in establishing a diagnosis. Oral candidiasis may present as pseudomembranous candidiasis, glossitis, or perlèche (angular cheilitis). Oral candidiasis is common in infants, but in adults it may signify immune deficiency or other illness. Herpes labialis typically is a mild, self-limited condition. Recurrent aphthous stomatitis most often is a mild condition; however, severe cases may be caused by nutritional deficiencies, autoimmune disorders, or human immunodeficiency virus infection. Erythema migrans is a waxing and waning disorder of unknown etiology. Hairy tongue represents elongation and hypertrophy of the filiform papillae and most often occurs in persons who smoke heavily. Oral lichen planus is a chronic inflammatory condition that may be reticular or erosive. Certain risk factors have been associated with each of these lesions, such as poor oral hygiene, age, tobacco use, and alcohol consumption, and some systemic conditions may have oral manifestations. Many recommended therapies for oral lesions are unsupported by randomized controlled trials.
The Surgeon General's report on oral health highlights the relationship between oral and overall health, emphasizing that oral health involves more than dentition.1 Physicians regularly encounter oral health issues in practice. For recognition and diagnosis of common oral lesions, a thorough history and a complete oral examination are required; knowledge of clinical characteristics such as size, location, surface morphology, color, pain, and duration also is helpful.
Large-scale, population-based screening studies have identified the most common oral lesions as candidiasis, recurrent herpes labialis, recurrent aphthous stomatitis, mucocele, fibroma, mandibular and palatal tori, pyogenic granuloma, erythema migrans, hairy tongue, lichen planus, and leukoplakia.2,3 This article, part I of a two-part series, reviews superficial mucosal lesions: candidiasis, herpes labialis, aphthous stomatitis, erythema migrans, hairy tongue, and lichen planus (Table 1).4–22 Part II covers masses and neoplasia.23
SORT: KEY RECOMMENDATIONS FOR PRACTICE
SORT: KEY RECOMMENDATIONS FOR PRACTICE
|Clinical recommendation||Evidence rating||References|
When treating recurrent herpes labialis with systemic antivirals such as acyclovir (Zovirax) or valacyclovir (Valtrex), therapy should be initiated during the prodrome. Topical penciclovir (Denavir) may help speed healing and reduce pain even if started after the prodrome.
Patients with severe recurrent aphthous stomatitis should be evaluated for possible underlying systemic diseases and vitamin deficiencies.
A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, see page 453 or http://www.aafp.org/afpsort.xml.
TABLE 1 Common Superficial Oral Lesions
Common Superficial Oral Lesions
Pseudomembranous: adherent white plaques that may be wiped off
Topical antifungals (e.g., nystatin [Mycostatin] suspension or troches, clotrimazole [Mycelex] troches, fluconazole [Diflucan] suspension, or systemic antifungals (e.g., fluconazole, ketoconazole [Nizoral], itraconazole [Sporanox])
Can confirm diagnosis with oral exfoliative cytology (stained with periodic acid-Schiff or potassium hydroxide), biopsy, or culture
Erythematous: red macular lesions, often with a burning sensation
Perlèche (angular cheilitis): erythematous, scaling fissures at the corners of the mouth
Prodrome (itching, burning, tingling) lasts approximately 12 to 36 hours, followed by eruption of clustered vesicles along the vermilion border that subsequently rupture, ulcerate, and crust
Immunocompetent patients usually do not require treatment
Reactivation triggers: ultraviolet light, trauma, fatigue, stress, menstruation
Topical agents include 1% penciclovir cream (Denavir)
Systemic agents (e.g., acyclovir [Zovirax], valacyclovir [Valtrex], famciclovir [Famvir]) are most effective if initiated during prodrome or as prophylaxis
Ulcers surfaced by a yellowish-white pseudomembrane surrounded by erythematous halo
Mild cases do not require treatment
Fluocinonide gel (Lidex) or triamcinolone acetonide (Kenalog in Orabase), amlexanox paste (Aphthasol), chlorhexidine gluconate (Peridex) mouthwash
Migrating lesions with central erythema surrounded by white-to-yellow elevated borders; typically on tongue
Asymptomatic cases do not require treatment
Symptomatic cases may be treated with topical corticosteroids, zinc supplements, or topical anesthetic rinses
Elongated filiform papillae
Regular tongue brushing or scraping; avoidance of predisposing factors
Predisposing factors include smoking and poor oral hygiene as well as antibiotics and psychotropics
Reticular: white, lacy striae
Asymptomatic cases do not require treatment
Buccal lesions typical in reticular form; other sites (e.g., tongue, gingiva) may be involved
Erosive: erythema and ulcers with peripheral radiating striae, erythematous and ulcerated gingiva
Symptomatic cases may be treated with a topical corticosteroid gel or mouth rinse
As many as 60 percent of healthy adults carry Candida species as a component of their normal oral flora. However, certain local and systemic factors may favor overgrowth. These include use of dentures, use of a steroid inhaler, xerostomia, endocrine disorders, human immunodeficiency virus (HIV) infection, leukemia, malnutrition, reduced immunity based on age, radiation therapy, systemic chemotherapy, and use of broad-spectrum antibiotics or corticosteroids.4–6,24,25
Oral candidiasis typically is a localized infection; however, rarely it may progress to or occur in patients with systemic candidiasis. Clinical patterns of oral candidiasis are variable and include pseudomembranous candidiasis, or thrush (Figure 1); median rhomboid glossitis and other forms of erythematous candidiasis (Figure 2); and perlèche, or angular cheilitis (Figure 3). Risk factors for systemic infection include acquired immunodeficiency syndrome, diabetes, hospitalization, immunosuppressive therapy, malignancy, neutropenia, organ transplantation, and prematurity.26,27
Oral candidiasis is common in infants, affecting 1 to 37 percent of newborns.28 Candidiasis in otherwise healthy infants manifests as a minor infection of the oral cavity, oropharynx, or skin (e.g., candidal diaper dermatitis).29 In contrast, candidiasis among preterm or hospitalized critically ill infants can, in rare instances, become systemic and potentially fatal.27 Chronic mucocutaneous candidiasis in infancy or early childhood can be associated with the development of autoimmune endocrine disorders, such as hypoparathyroidism, hypoadrenalism, hypothyroidism, and diabetes mellitus.5
Treatment involves topical or systemic antifungals. Commonly used topical regimens include nystatin (Mycostatin; not absorbed), clotrimazole (Mycelex troche), and systemic fluconazole (Diflucan). Randomized controlled trials have demonstrated fluconazole suspension to be more effective than nystatin in normal and immunocompromised children.7 Systemic agents such as fluconazole, ketoconazole (Nizoral), and itraconazole (Sporanox) may be used for patients who have candidiasis refractory to topical therapy, are intolerant of topical agents, or are at high risk of developing systemic infection.8,9
Primary oral infection with the herpes simplex virus (HSV) typically occurs at a young age, is asymptomatic, and is not associated with significant morbidity. A minority of persons develop a symptomatic primary infection, presenting with an acute outbreak of oral vesicles that rapidly collapse to form zones of erythema and ulceration. In all cases, the gingiva is involved; in addition, other oral mucosal sites and the perioral skin may be affected. Concomitant cervical lymphadenopathy, fever, chills, anorexia, and irritability are common findings.
After primary oral infection, HSV may persist in a latent state in the trigeminal ganglion and later reactivate as the more common herpes labialis, or “cold sores.” Common triggers for reactivation are well known and include ultraviolet light, trauma, fatigue, stress, and menstruation. These lesions affect approximately 15 to 45 percent of the U.S. population.10 They classically manifest as a well-localized cluster of small vesicles along the vermilion border of the lip or adjacent skin (Figure 4). The vesicles subsequently rupture, ulcerate, and crust within 24 to 48 hours. Spontaneous healing occurs over seven to 10 days.
In immunocompetent patients, herpes labialis usually is mild and self-limited. However, pain, swelling, and cosmetic concerns may prompt physician consultation. Orally administered antiviral agents, such as acyclovir (Zovirax) or valacyclovir (Valtrex), have a modest clinical benefit if initiated during the prodrome.10,11,30 Topical treatment with 1% penciclovir cream (Denavir) may reduce healing time and pain slightly, even if initiated after the prodrome.12,30 Reduction in healing time with systemic or topical agents is modest—approximately one day or less. Use of systemic antivirals for herpes labialis generally should be reserved for immunocompromised patients. Prophylactic treatment with oral antiviral medications may help patients who experience frequent recurrences, anticipate unavoidable exposure to a known trigger, or suffer from frequent episodes of postherpetic erythema multiforme.13,14,31,32 Recurrent herpetic infections should not be treated with corticosteroids.
Recurrent Aphthous Stomatitis
Recurrent aphthous stomatitis, or “canker sores,” is an oral ulcerative condition with a prevalence ranging from 5 to 21 percent.33 Although a variety of host and environmental factors have been implicated, the precise pathogenesis remains unknown. Smoking is associated with a lower prevalence, but other associations, such as nutritional deficiencies (e.g., vitamin B12, folate, iron), remain unclear.33 Severe cases may be related to underlying systemic conditions such as inflammatory bowel disease, celiac disease, Behçet's syndrome, and HIV infection.34,35
Recurrent aphthous stomatitis is characterized by recurring, painful, solitary or multiple ulcers, typically covered by a white-to-yellow pseudomembrane and surrounded by an erythematous halo (Figure 5). Recurrent aphthous stomatitis usually involves nonkeratinizing mucosa (e.g., labial mucosa, buccal mucosa, ventral tongue). There are three clinical forms: minor, major, and herpetiform. The minor form is the most common and appears as rounded, well-demarcated, single or multiple ulcers less than 1 cm in diameter that usually heal in 10 to 14 days without scarring.
Most patients with mild aphthae require no treatment or only periodic topical therapy. Commonly used therapies include topical corticosteroids, such as fluocinonide gel (Lidex) and triamcinolone acetonide with carboxymethylcellulose paste (Kenalog in Orabase). However, much of the evidence in support of these treatments is from small, incompletely blinded trials, and thus their effectiveness is uncertain.36,37 Chlorhexidine gluconate (Peridex) mouthwash decreases the severity of an episode but does not reduce the incidence of ulcers.15 Amlexanox 5% paste (Aphthasol) may promote healing and lessen pain.16 In severe or constantly recurring cases, systemic therapy with agents such as thalidomide (Thalomid) may be necessary. Because of the risk of serious adverse effects and its off-label status, thalidomide generally is reserved for severe cases such as those associated with HIV infection.17
Erythema migrans, which should not be confused with the characteristic rash of early Lyme disease, also is known as geographic tongue or benign migratory glossitis. A common oral inflammatory condition of unknown etiology, it has an estimated prevalence of 1 to 3 percent. The most commonly suggested associations are atopy and psoriasis.18 It usually affects the tongue, although other oral sites may be involved.
Erythema migrans may occur in children and adults and exhibits a female predilection. Tongue lesions exhibit central erythema caused by atrophy of the filiform papillae and usually are surrounded by slightly elevated, curving, white-to-yellow borders (Figure 6). The condition typically waxes and wanes, and the lesions demonstrate a migrating pattern. Some patients may complain of pain or burning, especially when eating spicy foods. However, most individuals are asymptomatic and do not require treatment for this benign condition. For symptomatic cases, several treatments have been proposed, including topical steroids, zinc supplements, and topical anesthetic rinses. None of these treatments has been proven to be uniformly effective.18
Hairy tongue is characterized by elongation and hypertrophy of the filiform papillae on the dorsal tongue, causing a hair-like appearance (Figure 7). This condition results from inadequate desquamation or increased keratinization of the papillae. These papillae, which normally are about 1 mm in length, may become as long as 12 mm. It occurs most often in persons who smoke heavily and it also may be associated with poor oral hygiene, oxidizing mouthwashes, Candida albicans, and certain medications.19–21
Although often called “black” hairy tongue, the condition may cause black, brown, or yellow discoloration depending on the foods ingested, tobacco use, and the amount of coffee or tea consumed. Rarely, patients may complain of gagging or of a metallic taste. Debris between elongated papillae can result in halitosis. Most cases improve with avoidance of predisposing factors and regular tongue brushing using a soft toothbrush or tongue scraper. Hairy tongue should not be confused with oral hairy leukoplakia, a condition characterized by vertical white striations typically affecting the lateral tongue bilaterally.
Oral lichen planus is a chronic waxing and waning inflammatory condition that affects an estimated 1 to 2 percent of adults. Although the etiology is uncertain, evidence suggests an immune-mediated mechanism involving CD8+ cytotoxic T-cell–induced apoptosis of epithelial cells.38 All age groups may be affected, but it predominates in adults older than 40 years, with a female-to-male ratio of 1.4:1.39
Two major clinical forms of oral lichen planus exist: reticular and erosive. The reticular form can appear as bilateral asymptomatic, white, lacy striations (Wickham's striae) or papules on the posterior buccal mucosa (Figure 8). The erosive form manifests as zones of tender erythema and painful ulcers surrounded by peripheral white, radiating striae (Figure 9A). It may also manifest as generalized erythema and ulceration of the gingiva, known as desquamative gingivitis (Figure 9B).
Classic lesions of reticular form often are readily identified clinically. However, lesions that do not exhibit classic features may require biopsy for diagnosis. Asymptomatic patients do not require treatment. For symptomatic patients, topical corticosteroid gels, such as fluocinonide and corticosteroid mouth rinses, may be prescribed.22 There is debate about whether oral lichen planus is associated with an increased risk of oral cancer.40 Therefore, periodic follow-up of patients is appropriate.
1. Evans CA, Kleinman DV. The Surgeon General's report on America's oral health: opportunities for the dental profession [Published correction appears in J Am Dent Assoc 2001;132:444]. J Am Dent Assoc. 2000;131:1721–8.
2. Shulman JD, Beach MM, Rivera-Hidalgo F. The prevalence of oral mucosal lesions in U.S. adults: data from the Third National Health and Nutrition Examination Survey, 1988–1994. J Am Dent Assoc. 2004;135:1279–86.
3. Bouquot JE. Common oral lesions found during a mass screening examination. J Am Dent Assoc. 1986;112:50–7.
4. Fotos PG, Vincent SD, Hellstein JW. Oral candidosis. Clinical, historical, and therapeutic features of 100 cases. Oral Surg Oral Med Oral Pathol. 1992;74:41–9.
5. Neville BW. Candidiasis. In: Oral and Maxillofacial Pathology. Philadelphia, Pa.: Saunders, 2002:189–97.
6. Epstein JB, Gorsky M, Caldwell J. Fluconazole mouth-rinses for oral candidiasis in postirradiation, transplant, and other patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002;93:671–5.
7. Pankhurst C. Candidiasis (oropharyngeal). Clin Evid. 2005;13:1701–16.
8. Patton LL, Bonito AJ, Shugars DA. A systematic review of the effectiveness of antifungal drugs for the prevention and treatment of oropharyngeal candidiasis in HIV-positive patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001;92:170–9.
9. Cha R, Sobel JD. Fluconazole for the treatment of candidiasis: 15 years experience. Expert Rev Anti Infect Ther. 2004;2:357–66.
10. Neville BW. Herpes simplex virus. In: Oral and Maxillofacial Pathology. Philadelphia, Pa.: Saunders, 2002:213–20.
11. Spruance SL, Jones TM, Blatter MM, Vargas-Cortes M, Barber J, Hill J, et al. High-dose, short-duration, early valacyclovir therapy for episodic treatment of cold sores: results of two randomized, placebo-controlled, multicenter studies. Antimicrob Agents Chemother. 2003;47:1072–80.
12. Raborn GW, Martel AY, Lassonde M, Lewis MA, Boon R, Spruance SL, et al., for the Worldwide Topical Penciclovir Collaborative Study Group. Effective treatment of herpes simplex labialis with penciclovir cream: combined results of two trials. J Am Dent Assoc. 2002;133:303–9.
13. Rooney JF, Straus SE, Mannix ML, Wohlenberg CR, Alling DW, Dumois JA, et al. Oral acyclovir to suppress frequently recurrent herpes labialis. A double-blind, placebo-controlled trial. Ann Intern Med. 1993;118:268–72.
14. Spruance SL. Prophylactic chemotherapy with acyclovir for recurrent herpes simplex labialis. J Med Virol. 1993;(suppl 1):27–32.
15. Porter S, Scully C. Aphthous ulcers (recurrent). Clin Evid. 2005;13:1687–94.
16. Greer RO Jr, Lindenmuth JE, Juarez T, Khandwala A. A double-blind study of topically applied 5% amlexanox in the treatment of aphthous ulcers. J Oral Maxillofac Surg. 1993;51:243–8.
17. Ramirez-Amador VA, Esquivel-Pedraza L, Ponce-de-Leon S, Reyes-Teran G, Gonzalez-Guevara M, Ponce-de-Leon S, et al. Thalidomide as therapy for human immunodeficiency virus-related oral ulcers: a double-blind placebo-controlled clinical trial. Clin Infect Dis. 1999;28:892–4.
18. Assimakopoulos D, Patrikakos G, Fotika C, Elisaf M. Benign migratory glossitis or geographic tongue: an enigmatic oral lesion. Am J Med. 2002;113(9):751–5.
19. Harada Y, Gaafar H. Black hairy tongue. A scanning electron microscopic study. J Laryngol Otol. 1977;91:91–6.
20. Heymann WR. Psychotropic agent-induced black hairy tongue. Cutis. 2000;66:25–6.
21. Sarti GM, Haddy RI, Schaffer D, Kihm J. Black hairy tongue. Am Fam Physician. 1990;41:1751–5.
22. Chan ES, Thornhill M, Zakrzewska J. Interventions for treating oral lichen planus. Cochrane Database Syst Rev. 1999;(2):CD001168.
23. Gonsalves WC, Chi AC, Neville BW. Common oral lesions. Part II: Masses and neoplasia. Am Fam Physician. 2007;75:509–12.
24. Ghannoum MA, Abu-Elteen KH. Pathogenicity determinants of Candida. Mycoses. 1990;33:265–82.
25. Abu-Elteen KH, Abu-Elteen RM. The prevalence of Candida albicans populations in the mouths of complete denture wearers. New Microbiol. 1998;21:41–8.
26. Hajjeh RA, Sofair AN, Harrison LH, Lyon GM, Arthington-Skaggs BA, Mirza SA, et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol. 2004;42:1519–27.
27. Shetty SS, Harrison LH, Hajjeh RA, Taylor T, Mirza SA, Schmidt AB, et al. Determining risk factors for candidemia among newborn infants from population-based surveillance: Baltimore, Maryland, 1998–2000. Pediatr Infect Dis J. 2005;24:601–4.
28. Goins RA, Ascher D, Waecker N, Arnold J, Moorefield E. Comparison of fluconazole and nystatin oral suspensions for treatments of oral candidiasis in infants. Pediatr Infect Dis J. 2002;21:1165–7.
29. Hoppe JE. Treatment of oropharyngeal candidiasis and candidal diaper dermatitis in neonates and infants: review and reappraisal. Pediatr Infect Dis J. 1997;16:885–94.
30. Worrall G. Herpes labialis. Clin Evid. 2004;12:2312–20.
31. Weston WL, Morelli JG. Herpes simplex virus-associated erythema multiforme in prepubertal children. Arch Pediatr Adolesc Med. 1997;151:1014–6.
32. Tatnall FM, Schofield JK, Leigh IM. A double-blind, placebo-controlled trial of continuous acyclovir therapy in recurrent erythema multiforme. Br J Dermatol. 1995;132:267–70.
33. Rivera-Hidalgo F, Shulman JD, Beach MM. The association of tobacco and other factors with recurrent aphthous stomatitis in an U.S. adult population. Oral Dis. 2004;10:335–45.
34. Neville BW. Recurrent aphthous stomatitis (recurrent aphthous ulcerations; canker sores). In: Oral and Maxillofacial Pathology. Philadelphia, Pa.: Saunders, 2002: 285–90.
35. Ogura M, Yamamoto T, Morita M, Watanabe T. A case-control study on food intake of patients with recurrent aphthous stomatitis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001;91:45–9.
36. Scully C. Clinical practice. Aphthous ulceration. N Engl J Med. 2006;355:165–72.
37. Pimlott SJ, Walker DM. A controlled clinical trial of the efficacy of topically applied fluocinonide in the treatment of recurrent aphthous ulceration. Br Dent J. 1983;154:174–7.
38. Sugerman PB, Savage NW, Zhou X, Walsh LJ, Bigby M. Oral lichen planus. Clin Dermatol. 2000;18:533–9.
39. Axell T, Rundquist L. Oral lichen planus—a demographic study. Community Dent Oral Epidemiol. 1987;15:52–6.
40. Eisen D. The clinical features, malignant potential, and systemic associations of oral lichen planus: a study of 723 patients. J Am Acad Dermatol. 2002;46:207–14.
Copyright © 2007 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact email@example.com for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions